Market Research Blog – Page 15209 – New Product Development

Oxycodone Market will rise consistently at 4.8% CAGR over 2031

ESOMAR-certified consulting firm Future Market Insight (FMI) has published a report on the global oxycodone market for the forecast period of 2021 – 2031. According to the report, the market is expected to expand at a CAGR of 4.8% during the forecast period.

Oxycodone belongs to a group of opioid analgesics that is generally used in pain management. It is used for both long and short term. Rising prevalence of orthopaedic diseases such as osteoporosis, fibromyalgia, rheumatoid arthritis and other types of chronic pain is boosting the demand for oxycodone in the global market.

According to the International Osteoporosis Foundation, osteoporosis is one of the most serious health concerns among women and around 30% of people in U.S and Europe are affected by it each year. Increasing medical ailment and post-operative pain is another factor influencing the demand for oxycodone market globally.

The market growth is expected to accelerate due to increasing research and development activities undertaken to innovate abuse-deterrent formulations. Advance drug formulation such as extended-release medication for pain relief is an example of improve formulation.

The market however could face certain restrains in growth as oxycodone has side effects such as bladder pain, abdominal cramps, vomiting, diarrhoea, and breathing problem. Moreover, overdose of oxycodone can lead to de-addiction. The market can also be impacted due to certain severe adverse psychological problems such as depression.

COVID-19 pandemic has affected healthcare industry as there has been a sharp reduction in demand due to lesser visits to healthcare facilities such as clinics and hospitals. The widespread of virus has affected workforce in hospitals and other staffing issues as well.

Key Takeaways from FMI’s Oxycodone Market Study

Increasing penetration of pain management drugs, coupled with favourable reimbursement policies will drive sales in the U.S.
Within the Middle East and Africa, the demand in GCC countries will rise backed by investment towards expansion of the healthcare sector
The U.K., Italy, and France are likely to account for sizeable share in the Europe market for oxycodone

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7638

Long-acting oxycodone sales will rise steadily owing to surging application in pain management
Hospital pharmacies will continue exhibiting high demand for oxycodone, driven by higher footfall of patients

Who is Winning?

The key payers operating in the global oxycodone market are focusing on adopting numerous strategies such as mergers and acquisitions, research and development activities, and joint ventures. The key players operating in the global market are Janssen Pharmaceuticals (A Johnson and Johnson Subsidary), Inc., Purdue Pharma L., Hikma Pharmaceuticals USA, Inc., Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Sanofi-Aventis S.A., and others.

FDA in 2017 approved RoxyBond, a novel formulation of immediate-release oxycodone. This is the first approved immediate release opioid analgesic formulation with labelling that describes its abuse-deterrent properties.
In September 2019, Daiichi Sankyo Company in Japan, launched its generic formulated oxycodone hydrochloride hydrate extended release tablets for cancer pain treatment.

More Insight on the Global Oxycodone Market

In the latest study, Future Market Insights gives a detailed insight on the global oxycodone market, providing historical data for the period from 2016 to 2020 and forecast statistics for the period of 2021 – 2031. To understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (long-acting oxycodone and short-acting oxycodone), application segment (pain management and de-addiction), distribution channel (hospitals pharmacies and retail pharmacies), and region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-7638

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Ocular Drug Delivery System Market is forecast to exhibit 6.8% CAGR between 2021 and 2031

According to Future Market Insights (FMI), the demand for ocular drug delivery system is expected to rise considerably, enabling the market to surpass US$ 14,471.2 Mn in valuation by the end of 2021. The market is forecast to exhibit 6.8% CAGR between 2021 and 2031.

Ocular drug delivery systems are designed for dispensing drug, biologic, biopharmaceutical, and botanical therapeutics for treating macular degeneration, glaucoma, presbyopia, allergy, anti-viral, dry eye, anti-infective and anti-inflammatory indications.

To overcome the ocular drug delivery barriers and improve ocular bioavailability, various conventional and novel drug delivery systems have been developed such as ointments, emulsion, suspensions, aqueous gels, Nano micelles, liposomes, , and in situ thermosensitive gels for the earlier mention ocular diseases.

Glaucoma is the second-leading cause of blindness worldwide, accounting for up to 8% of total blindness. In India, glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. More than 90 percent of glaucoma cases remain undiagnosed in the community.

Thus the high incidence of ophthalmic diseases, resulting in the rise significant patient population, is driving the global ocular drug delivery systems market.

Ocular drug has to pass the water-fat-water membranous structure of cornea and this changing environment presents a significant barrier. That is why, for almost four decades, researchers have been involved in developing intraocular sustained-release drug delivery platforms.

Owing to the rigorous research studies, approvals for new ocular drug delivery techniques are currently recorded globally. This has helped the market to gain momentum over the last few years.

Key Takeaways from Ocular Drug Delivery System Market Study

Increasing focus on pharmaceutical innovation and research on drug delivery technologies is driving a transition towards particulate drug delivery systems, which will account for over 68% of the market in 2021.
Ophthalmic solution for ocular drug delivery system is expected to account for 60% the global market share by 2031.
Among distribution channels, hospital pharmacies accounted for 40% of the market share in 2031. Soaring influx of patients for treatment and availability of intensive care support have propelled the demand in the sehment.
North America holds the maximum share, owing to the presence of Tier1 players, high per-capita healthcare expenditure, and favorable reimbursement policies in the region.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-6027

The U.S. holds a more than 44% share in the global ocular drug delivery systems market.
The U.K. and Germany are leading markets in Europe, accounting for more than 41% of the Europe market in 2021.
South Korea is the fastest growing market in East Asia, exhibiting 10.3% CAGR through 2031.

Increase in Funding for Research Activities Offers Growth Opportunities

Leading manufacturers in the ocular drug delivery system market are strengthening their market position through collaboration with various other organizations. Governments in developed and developing countries are actively taking initiatives to encourage research pharmaceutical products.

For instance, In April, 2017, Santen Pharmaceuticals announced a strategic investment in Regenerative Patch Technologies LLC, a U.S. based company engaged in development of ophthalmic therapies.

Pharmaceutical giants are expected to benefit from the globalization of labor forces, that is, employment of skilled local labor at cheaper rates to derive larger cost savings. Furthermore, this will create room for research and development (R&D) investments.

As per data from EFPIA and PhRMA, annual pharmaceutical (R&D) expenditures increased at 2.5% p.a. in Europe as compared to 3.3% p.a. in the U.S. over the latest measurable period 2016-2020. This will also create opportunities for the expansion of the market.

Who is Winning?

The global market is set to expand due to the rising prevalence of eye infections. Leading players within this space are expected to focus on research and development to offer an early and precise diagnosis of ailment, besides offering effective patient care.

Some of the leading players in the ocular drug delivery system market include but are not limited to Allergan Plc., Graybug Vision Inc., Ocular Therapeutix, Inc., Alimera Sciences, pSivida, Santen Pharmaceutical Co., Ltd, Taiwan Liposome Company Ltd., Envisia Therapeutics, Eyegate Pharma, Valeant Pharmaceuticals International, Inc, Vision Ophthalmology Group GmbH, Clearside Biomedical, URSAPHARM Arzneimittel GmbH.

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global ocular drug delivery systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the ocular drug delivery systems treatment on basis of the key indication in detail, cover every aspect of the market such as technology, dosage form, distribution channel across seven major regions.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-6027

Pertussis Infection Testing Market Expected to Witness High Growth by 2029

Pertussis Infection Testing Market Overview

Pertussis Infection Testing : Market Insights

Pertussis refers to the whooping cough, which can lead to a serious illness in children and in adults as well. The common symptoms of pertussis includes vomiting, coughing fits, whooping, long pause in breathing, presence of blue or purple skin color due to lack of oxygen, fever etc.

Pertussis is one of the common infectious disease which can be treated by vaccine. It occurs more commonly in the children younger than 5 years of age. According to center for Disease Control and Prevention, there are approximately 175,000 cases of pertussis each year. According to World Health Organization, there were 195,000 deaths from pertussis infection.

The bordetella pertussis IgM ELISA testing kits, PCR instruments and various other instruments are used in the diagnosis of pertussis infection. FluoroType Bordetella instrument is manufactured by Hain Lifescience Gmbh. It is highly sensitive and specific instrument. It is rapid as result or outcome is obtained within three hours.

There are three stages of pertussis infection. The first stage of the pertussis is the running nose. The first phase lasts for one to two weeks. The second stage of the pertussis is the paroxysmal stage. The duration of this phase varies from patient to patient. The last or the third stage of this disease is convalescent stage. The last stage can lasts for few weeks or months and it might get to a serious level of chronic cough.

Pertussis Infection Testing: Market Dynamics

The increasing prevalence of pertussis, especially in children, is expected to increase the growth of pertussis infection testing market. It is estimated that 20 to 40 million persons are newly infected with pertussis each year, 90 % of cases thereof occur in developing countries. Increasing number of diagnostic laboratories, is another important factor which can increase the growth of pertussis infection testing market. There are various other factors such as increasing number of hospitals, increasing unhygienic conditions in the hospitals, increasing availability of the pertussis testing kits for the treatment of pertussis etc. can be responsible for the significant growth of pertussis infection testing market. Increasing healthcare awareness among the people and increasing per capita healthcare expenditure, are expected to increase the growth of pertussis infection testing market. Increasing disposable income, can also increase the growth of pertussis infection testing market.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10566

There are a few factors which can hinder the growth of pertussis infection testing market. Various factors such as poor availability of the pertussis testing Elisa kits in some of the laboratories, can hinder the growth of pertussis infection testing market. Other factors such as lack of awareness of the pertussis infection testing, especially in some of the developing regions, can hinder the overall growth of pertussis infection testing market. High price of pertussis testing kits can also hinder the overall growth of pertussis infection testing market.

Pertussis Infection Testing Market: Overview

The pertussis infection testing market has been segmented on the basis of its product type and end user. On the basis of products, the pertussis infection testing market has been segmented into reagent & kits and instruments. FluoroType bordetella instrument is involved in the rapid identification of B. pertussis. Pertussis infection testing kits hold a large revenue share in the overall market. Based on the end user, the pertussis infection testing market has been segmented into hospitals, specialty clinics, diagnostic laboratories and research centers. Diagnostic laboratories, is expected to hold a large revenue share in the pertussis infection testing market.

Pertussis Infection Testing Market: Key Players

There are many companies associated with the manufacturing of Pertussis Infection Testing market. The key players operating in the Pertussis Infection Testing market follow various promotional strategies such as development of new and advanced products and partnerships with other companies. Some of the key players present in global Pertussis Infection Testing market are Tecan Trading AG, Cortez Diagnostics Inc., Hain Lifescience GmbH, bioMerieux SA etc.

The report covers exhaustive analysis on:

Pertussis Infection Testing Market Segments
Pertussis Infection Testing Market Dynamics
Pertussis Infection Testing Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC, S. Africa, N. Africa)

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-10566

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Homocysteine Testing Market Prospects and Growth Assessment 2029

Homocysteine Testing Market Overview

Homocysteine Testing: Market Insights

Homocysteine is a building block of protein i.e. a common amino acid that produced in the blood. High levels of homocysteine can lead to the early development of heart-related disorders, renal disease, and can cause deficiency of vitamins B6, vitamin B12, and folate. Homocysteine testing can be simply measured doing a blood test. Generally, vitamin B6, vitamin B12, and folate break down homocysteine and convert it into other substances. The body receives homocysteine mostly from meat. Growing meat consumption has increased the level of homocysteine in the body. This has upsurge the risk of heart and renal disease and deficiency of vitamin B6, vitamin B6 and folic acid in the body of an individual. To reduce the burden, regular homocysteine testing is required which can be detected through a simple blood test. Hence, it is recommended to do the body checkup and blood testing at least once in three months.

Homocysteine Testing: Market Dynamics

Rising geriatric population, increasing alcohol consumption, smoking, and use of vitamin B supplements are some of the driving factor for propelling the growth of homocysteine testing market. The world’s ageing population is growing at an unprecedented rate. Today, around 8.5% of the population are over 65 years and above, globally. This significantly will increase the growth of homocysteine testing market in the forecast period. Additionally, the rise in disposable income is increasing the treatment-seeking rate after diagnosis. This factor is expected to propel the growth of the homocysteine testing market. However, unsymptomatic nature and unable to detect the high level of homocysteine at an early stage can lead to severe heart conditions and may hamper the growth of the homocysteine testing market. Also, unawareness regarding the deficiency of vitamins in the blood until becoming severe may limit the growth of the homocysteine testing market.

Homocysteine Testing: Overview

High level of homocysteine usually shows a deficiency in vitamin B12 or folic acid. In blood, a normal homocysteine level should be less than 15 micromoles/litre of blood. Higher homocysteine levels can be categorized into moderate in which homocysteine level is ~15-30 micromoles/litre of blood, intermediate in which homocysteine level reach ~30-100 micromoles/litre of blood, and severe in which homocysteine level reach more than 100 micromoles/litre of blood. If an individual detected with a high level of homocysteine, some other homocysteine testing is required to done to confirm the homocysteine level. Moreover, poor lifestyle, changing demographics, and increasing junk food consumption are some of the key factors driving the market growth of homocysteine testing market.

Homocysteine Testing: Region-wise Outlook

The Asia-Pacific homocysteine testing market is expected to grow at a moderate growth, however, is likely to show a large patient pool in the forecast years. This is because of a high percentage of the population lack awareness regarding the management of the level of homocysteine testing, which restricts them to opt for homocysteine testing. This factor is expected to hamper the market growth of homocysteine testing in the region. The North America market is expected to show high homocysteine testing market growth because the compliance rate of blood testing in the region is high coupled with progressive healthcare infrastructure and large treatment-seeking population in the region. Europe market will be in second place in the homocysteine testing market due to the high adoption rate for homocysteine testing.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10563

Homocysteine Testing: Key Players

Some of the key players present in global homocysteine testing market are Mylan Pharmaceuticals, Bristol-Myers Squibb Company, Novartis International AG, Teligent, Inc., Pfizer Inc., Cardinal Health, Inc., McKesson Corporation, Jamp Pharma Corporation, Kripps Pharmacy Ltd, and others.

The report covers exhaustive analysis on:

Homocysteine Testing Market Segments
Homocysteine Testing Market Dynamics
Homocysteine Testing Market Size
Homocysteine Testing Current Trends/Issues/Challenges
Homocysteine Testing Competition & Companies involved
Homocysteine Testing Value Chain

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of Latin America)
Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Russia, Rest of Europe)
East Asia (China, Japan, South Korea)
South Asia (India, Indonesia, Malaysia, Rest of East Asia)
Middle East and Africa (N. Africa, S. Africa, Israel, Rest Of MEA)

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-10563

Pancreatic Stone Protein Testing Market:Technological Growth Map over Time

Pancreatic Stone Protein Testing Market Overview

Different pancreatic secretory proteins have been identified in the last decade. That is protein X, human pancreatic thread protein (PTP), and pancreatic stone protein (PSP). Among them, pancreatic stone protein has been reported to play a crucial role in the development of pancreatic stone. Pancreatic stone protein testing has been very useful for diagnosis and early management of stone formation in chronic pancreatitis. Pancreatic stone protein testing has been analyzed using several assay techniques such as ELISA, fluorometric immunoassay and enzyme immunoassay. A life-threatening syndrome is known as Sepsis resulting in multiple organ dysfunction. That is characterized by the deregulated host response to an infection. According to WHO sepsis affects more than 30 million people worldwide every year. Leading to 6 million deaths. The occurrence of sepsis is most likely highest in low- and middle-income countries. However, for the diagnosis of sepsis, pancreatic stone protein testing is showing great promises. Pancreatic stone protein has been used as a marker for the early detection and diagnosis of sepsis. Also, pancreatic stone protein has been used as a novel protein biomarker for the diagnosis of several other diseases related to pancreatic stone formation due to infection. Pancreatic stone protein testing is also helping in early diagnosis and management of diseases such as acute appendicitis and other wolfram syndromes such as diabetes insipidus, diabetes mellitus, optic atrophy etc.

Pancreatic Stone Protein Testing Market: Driver and Restraints

The increasing cases of chronic diseases due to pancreatic stone formation expected to drive the market of pancreatic stone protein testing. The prevalence of diseases such as acute appendicitis, diabetes and optic atrophy drives the pancreatic stone protein testing market worldwide. Change in lifestyle, increasing consumption of alcohol promotes acute pancreatitis, which expected to drive the pancreatic stone protein testing market. However, the symptoms of acute pancreatitis are nonspecific and biomarker such as pancreatic stone protein testing is high sensitivity and specificity are still lacking despite extensive research. Further, the cost-effectiveness, sensitivity, accuracy, and specificity of the pancreatic stone protein testing expected to restrain the pancreatic stone protein testing market.

Pancreatic Stone Protein Testing Market: Overview

The market of pancreatic stone protein testing is very demanding globally because of its importance of used as a biomarker for the early detection of various life-threatening diseases. The symptoms of acute pancreatitis rate are higher in developing countries as well as in developed countries. Due to the change in lifestyles, irregular and unhealthy food consumption develops diseases such as sepsis, acute appendicitis and Wolfram syndrome worldwide. Consequently, the global market of pancreatic stone protein testing will expectedly grow vigorously in the near forecasting periods. The global key players have immense opportunity to develop assay kits and other immunoassay devices for the evaluation of pancreatic stone protein testing.

Pancreatic stone protein testing Market: Key Market Participants

Ray Biotech, Inc., Thermo Fisher Scientific, Inc. Lifespan Biosciences Inc., Abnova Corporation, Amsbio LLC. (AMS Biotechnology (Europe) Ltd), CUSABIO TECHNOLOGY LLC, Boster Biological Technology, United States Biological Inc., Creative Diagnostics Inc., Abbexa Ltd., Aviva Systems Biology Corporation, among others.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10562

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Pancreatic Stone Protein Market Segments
Pancreatic Stone Protein Market Dynamics
Pancreatic Stone Protein Market Size
Pancreatic Stone Protein Supply & Demand
Pancreatic Stone Protein Current Trends/Issues/Challenges
Pancreatic Stone Protein Competition & Companies involved
Pancreatic Stone Protein Technology
Pancreatic Stone Protein Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, China ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-10562

Gamma Glutamyl Transferase Testing Market to Garner Brimming Revenues by 2029

Gamma Glutamyl Transferase Testing Market Overview

Gamma glutamyl transferase testing involves the quantitative assessment of gamma glutamyl transferase. This is a membrane protein which catalyze the transfer of glutamyl to amino acids or peptides. The gamma glutamyl cycle is a pathway in which the glutathione homeostasis and detoxification of xenobiotics is carried out. The level of gamma glutamyl transferase (GGT) increases in the serum in conditions such as cardiovascular disease, liver dysfunction or disease and other metabolic syndromes. In general the gamma glutamyl transferase testing is prescribed by the doctor when liver damage or liver disease is suspected especially in case of alcohol abuse. Low appetite, vomiting or nausea, fatigue, abdominal pain, jaundice, dark urine, and itchy skin are some of the most common symptoms of liver disorders and diseases. Alcohol hepatitis is the most common liver disorder diagnosed using the gamma glutamyl transferase testing.

Oxidative stress can also be asses using gamma glutamyl transferase testing. Apart from liver damage, gamma glutamyl testing can also be used to assess elevated levels of gamma glutamyl transferase due to kidney, pancreas and biliary system diseases. Alcohol abuse and abuse of certain medications also can be asses by the elevated levels of GGT through the gamma glutamyl transferase testing. However, the gamma glutamyl transferase testing is not a standalone test. The gamma glutamyl transferase testing is often followed by other blood tests such as ALT and AST that is also known as SGOT and the bilirubin test. None the less the gamma glutamyl transferase testing is a valuable testing method for uncovering many silent liver diseases that may otherwise go undiagnosed.

The alkaline phosphatase (ALP) test is generally conducted in correlation with the gamma glutamyl transferase testing. Elevated levels of both the GGT and ALP is indicative towards issues with the liver or bile. Normal level of GGT and elevated level of ALP is indicative towards a bone disease. Thus the gamma glutamyl transferase testing is also used to rule out certain diseases. Elevated levels of GGT is indicative towards alcohol abulse, hepatitis, improper blood flow to liver, liver cancer, liver cirrhosis, drug abuse or drug related liver toxicity, heart failure, diabetes, pancreatitis and fatty liver disease.

Gamma Glutamyl Transferase Testing Market: Drivers and Restraints

Rising prevalence of cardiovascular diseases, liver disorders and diseases as well as rise in alcohol consumption globally are some of the factors that drive the growth of the gamma glutamyl transferase testing market. However, availability of alternative testing methods could hinder the growth of the gamma glutamyl transferase testing market. Furthermore, need for secondary and confirmatory testing may impact the growth of the gamma glutamyl transferase testing market negatively.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10578

Gamma Glutamyl Transferase testing Market: Overview

The colorimetric type of gamma glutamyl transferase testing kits are most commonly used kits. This is primarily due to the lower cost when compared to the ELISA based test kit. Assay kits are easy to use, they are convenient, simple and require no or little time for optimization. The gamma glutamyl transferase is generally conducted as a blood test and is highly accurate and sensitive to alcohol, medication and smoking. Treatment for elevated levels of GGT involves lifestyle changes, change in diet and medication. The gamma glutamyl transferase testing is not a standalone test however is a highly accurate and sensitive test that can also be used for ruling out certain disease. The gamma glutamyl transferase testing can also be used for tissue lysates and cell lysates for research and diagnostic purposes.

Gamma Glutamyl Transferase testing Market: Key Players

Some of the key players in the gamma glutamyl transferase testing market include, Merck KGaA, BioVision Inc., Creative BioMart, PromoCell, Abnova Corporation, XpressBio, Abbkine, Inc., MyBioSource, among others.

The report covers exhaustive analysis on:

Gamma glutamyl transferase testing market Segments
Gamma glutamyl transferase testing market Dynamics
Gamma glutamyl transferase testing market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain
Disease epidemology

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of Latin America)
Europe (Germany, Italy, France, U.K, Spain, Russia, Rest of Europe)
East Asia (China, Japan, South Korea)
South Asia (India, Malaysia, Thailand, Indonesia, Rest of South Asia)
Oceania (Australia & New Zealand)
The Middle East and Africa (GCC, S. Africa, N. Africa, Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-10578

Blood Urea Nitrogen Diagnostics Market to Witness a Healthy Growth by 2029

Blood Urea Nitrogen Diagnostics Market Overview

The blood urea nitrogen diagnostics test is a fairly common blood test, which is used for assessing the condition of the kidneys and liver. The blood urea nitrogen diagnostics test measures the quantity of urea nitrogen in the blood. The urea nitrogen is excreted from the body through a cascade of reactions. Ammonia produced by the liver by breaking down the proteins consumed by the body cells. Nitrogen from the ammonia combines with elements such as hydrogen, carbon and oxygen that results in the formation of urea. This is a chemical waste of the body. The blood caries the urea from the liver to the kidney where it is filtered out along with other waste products to form urine that is finally excreted out from the body. Thus a blood urea nitrogen diagnostics test is used to asses if the quantity of nitrogen in the blood is higher than normal. The high value may indicate that the kidney function is hampered. Commonly the blood urea nitrogen diagnostics is conducted when the doctor suspects kidney damage, or during general kidney function evaluation. The blood urea nitrogen diagnostics is also used to determine the effectiveness of dialysis treatments such as hemodialysis or peritoneal dialysis. Other conditions such as liver damage, obstruction in the urinary tract, congestive heart failure and gastrointestinal bleeding can also be asses using the blood urea nitrogen diagnostics. However this test alone may not be able to assess the type of condition and may require confirmatory tests. For an instance, to assess and confirm kidney damage a creatinine level test is also performed along with the blood urea nitrogen diagnostics. Creatinine is also another waste product excreted out from the blood into through the urine. To assess the present kidney function glomerular filtration rate is estimated by calculating the amount of waste taken out of the blood. 7-20 mg/dL or 2.5-7.1 mmol/L is the normal concentration of urea nitrogen in the blood.

Blood Urea Nitrogen Diagnostics Market: Drivers and Restraints

Some of the factors that contribute to kidney damage and cases when a blood urea nitrogen diagnostics can be used include, old age, obstruction in urinary tract, recent heart attack or congestive heart failure, bleeding in the gastrointestine, dehydration, trauma, severe burns, adoption of a high protein diet and intake of certain antibiotics. Thus rise in the above conditions among the population crates a large pool of patients thereby driving the growth of the blood urea nitrogen diagnostics market.

Blood Urea Nitrogen Diagnostics Market: Overview

Assay kits are the most common type of product that is used for blood urea nitrogen diagnostics. However the adoption of ELISA and other methods vary significantly across regions. This is primarily due to the price difference between the two types of technologies. Among end users hospitals and diagnostic laboratories are together expected to continue dominating the market through the forecast period.

Blood Urea Nitrogen Diagnostics Market: Key Players

Some of the key players in the blood urea nitrogen diagnostics market include, Pointe Scientific, Inc., Accurex biomedical Pvt. Ltd., Invitrogen, Beacon Diagnostics Pvt. Ltd., Thermo Fisher Scientific, Eagle Biosciences, Inc., XpressBio, and Bioo Scientific Corporation, among others.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10575

The report covers exhaustive analysis on:

Blood urea nitrogen diagnostics market Segments
Blood urea nitrogen diagnostics market Dynamics
Blood urea nitrogen diagnostics market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain
Disease epidemology

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of Latin America)
Europe (Germany, Italy, France, U.K, Spain, Russia, Rest of Europe)
East Asia (China, Japan, South Korea)
South Asia (India, Malaysia, Thailand, Indonesia, Rest of South Asia)
Oceania (Australia & New Zealand)
The Middle East and Africa (GCC, S. Africa, N. Africa, Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-10575

Candida Vaginitis Rapid Testing Market to Witness Stunning Growth by 2029

Candida Vaginitis Rapid Testing Market Overview

Candida vaginitis is generally characterized by pruritus, vaginal soreness and discharge along with dyspareunia. A microscopic examination of vaginal secretions with 10% potassium hydroxide has shown to have a sensitivity of about 65-85%. Vaginal culture test is recommended for patients with recurrent symptoms and negative microscopic test. The candida vaginitis infection does not change the pH of the vagina. The symptoms for bacterial vaginitis are the same as that of candida vaginitis. Thus a pH test for candida vaginitis is recommended when the infection symptoms are significantly clear to differentiate of the infection is caused by bacteria or candida. These candida vaginitis rapid tests such as the pH tests and immunoassay tests cost less than $10 when compare to the $65 candida culture test. The PCR based test for candida vaginitis has been proved by various studies that it is the most sensitive test, however it is also the most expensive making it suitable for use of candida vaginitis rapid testing to be the most convenient and cost effective testing methods available for first line diagnostics.

Candida vaginitis rapid testing Market: Drivers and Restraints

Candida vaginitis is a relatively common problem seen in the women population. Studies report that about 75% women have the infection at least once in their lifetime in the U.S. Furthermore, about half of them suffer from recurrent infections and 5% develop chronic conditions. Due to this significant patient pool the market for candida vaginitis rapid testing market is expected to continue to thrive. Furthermore, advancement in technology and pipeline products that are expected to launch in the near future will further support the growth of the candida vaginitis rapid testing market. However, relatively high cost of the candida vaginitis rapid testing kits and lack of awareness may hinder the growth of the candida vaginitis rapid testing market. Also availability of alternative testing methods may also affect the candida vaginitis rapid testing market growth negatively.

Candida vaginitis rapid testing Market: Overview

Among the segments of the candida vaginitis rapid testing market, the immune assay based candida vaginitis rapid testing kits has seen more success than the pH based tests. This is primarily due to the better accuracy and assurance of results than the pH based candida vaginitis rapid testing kits offer. Furthermore, although urine samples are more easily available sample for testing vaginal swabs offer more accurate results, making it the most commonly used sample type for candida vaginitis rapid testing. These candida vaginitis rapid tests can be used in hospitals, clinics as well as in home care settings. Most manufacturers offer different packaging for the OTC product and the POCT product. While the OTC candida vaginitis rapid testing kit has a single test kit package for home use the POCT product often comes in 10 or 20 test kit package for office use.

Candida vaginitis rapid testing Market: Key Players

Some of the key players in the candida vaginitis rapid testing market include, Combe Incorporated, Quest, Quest Diagnostics, Prestige Consumer Healthcare Inc., Becton Dickinson, JD Biotech, NanoRepro AG, and Savyon Diagnostics Ltd, among others.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10572

The report covers exhaustive analysis on:

Candida vaginitis rapid testing Market Segments
Candida vaginitis rapid testing Market Dynamics
Candida vaginitis rapid testing Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain
Disease epidemology

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of Latin America)
Europe (Germany, Italy, France, U.K, Spain, Russia, Rest of Europe)
East Asia (China, Japan, South Korea)
South Asia (India, Malaysia, Thailand, Indonesia, Rest of South Asia)
Oceania (Australia & New Zealand)
The Middle East and Africa (GCC, S. Africa, N. Africa, Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-10572

Urinary Protein Reagents Market Revenue Growth Predicted by 2029

Urinary Protein Reagents Market OverviewUrinary protein reagents used for the quantitative measurement of the total protein in human urine. Protein quantification in the urine is important in the diagnosis of several renal and cardiac diseases. The normal urine protein level is less than 150mg/day and less than 30 mg of albumin per day. Excessive presence of protein in the urine is categorized as proteinuria. An excessive amount of urinary protein also presents the condition like urinary tract infection, diabetic nephropathy, nephritis, monoclonal gammopathies. Urinary protein reagents are used in colourimetric, turbidimetric, electrophoretic diagnosis procedures to examine protein contained in the urine. The increasing number of kidney disorder and urinary tract infection increase the demand for diagnostic tests and favour the growth of the urinary protein reagents market. In kidney damage cases level of albumin increases that is the key parameter for the early detection of the kidney disorder

Urinary Protein Reagents Market: Drivers and Restraints-

The increasing number of kidney disorders with age and high consumption of alcohol demands regular urinary protein testing for observational purpose. Introduction of the new testing method, adoption of new technologies for diagnostic testing influence the growth of the urinary protein reagents market. Increasing recommendation for the regular urine testing by healthcare professionals and growing awareness among general population expected to boost up the growth of the urinary protein reagents market. Increasing per capita healthcare expenditure, healthcare parameter testing campaign expected to drive the growth of the urinary protein reagents market. Increasing demand for the laboratory-based diagnostic methods and growing diagnostic healthcare budget are some of the factors propelling the growth of the urinary protein reagents market. Increasing prevalence of chronic diseases such as diabetes and hypertension favors the growth of the urinary protein reagents market.

Urinary Protein Reagents Market: Overview

Urinary protein reagents market expected to grow with the significant growth rate as growing demand for urinary protein testing for the diagnosis of various disorders. Urinary protein reagents are gaining prominent demand for different diagnostic methods and procedures. Urinary protein reagents are gaining high demand for urinary tract infections and nephrosis testing. Hospital and diagnostic laboratories expected to contribute higher revenue share in the urinary protein reagents market as high number of test performed in the hospitals and diagnostic centers.

Urinary Protein Reagents Market: Key Market Participants

Example of some market players participants in global urinary protein reagents market find across the value chain are Thermo Fisher Scientific, Randox Laboratories, Beckman Coulter Inc. (Danaher Corporation), Sigma-Aldrich Corporation (Merck KGaA)., Bioassay Systems LLC, PerkinElmer, Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Quantimetrix Corporation, Sclavo Diagnostics International Spa, Sentinel Diagnostics – Sentinel CH. S.p.A., ELITechGroup and others.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10631

The report covers exhaust analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, China ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

A detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current, and projected market size regarding volume and value
Recent industry trends and developments for Urinary Protein Reagents Market
Competitive landscape for Urinary Protein Reagents Market
Strategies for key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-10631

Total Iron-Binding Capacity Reagents Market to Grow at Robust CAGR by 2029

Total Iron-Binding Capacity Reagents Market Overview

Total iron-binding capacity assays are used for the measurement capacity of serum molecule to bind the number of iron molecules. The total iron-binding capacity is used to evaluate the total iron content in the body and whether the body functions normally or not. Total iron-binding capacity is often reflects the blood flow and related disorders. Normal total iron-binding capacity indicates the normal blood flow to all the body organs and normal functioning of the body. Abnormal total iron-binding capacity often indicates the iron deficiency anemia and blood related disorders. As per World Health Organization, the total incidence of the iron deficiency anemia is ranges from 7.2 to 13.6 per 1,000 people.

Total Iron-Binding Capacity Reagents Market: Drivers and Restraints

Increasing prevalence of the iron deficiency anemia is expected to drive the growth of the total iron-binding capacity reagents market. Iron deficiency anemia is often common in the women due to various factors such as menstrual cycle, increasing awareness among the women about the disorder further expected to drive the growth of the total iron-binding capacity reagents market.

Chemotherapy often results in anemia and out of total anemic patients few also suffer from iron deficiency anemia and to evaluate the total number of patients with iron deficiency anemia as well as its severity, which in turn expected to drive the growth of the total iron-binding capacity reagents market across the world. Cancer and related therapies such as chemotherapy, radiotherapy often depletes iron stores which in turn expected to drive the growth of total iron-binding capacity reagents market. Increasing treatment seeking rate across the world in cancer patients expected to drive the growth of total iron-binding capacity reagents market. Increasing awareness about the iron deficiency anemia expected to drive the growth of the total iron-binding capacity reagents market. Whereas, limited product availability and time consuming nature of the total iron-binding capacity assays may hamper the [potential growth of the total iron-binding capacity reagents market. Increasing R & D expenditure to evaluate the effective way to identify the total iron content in the body further expected to drive the growth of total iron-binding capacity reagents market.

Total Iron-Binding Capacity Reagents Market: Overview

The global total iron-binding capacity reagents market is expected to witness steady growth over the forecast period owing to increasing product penetration in the different regions. By disease type, iron deficiency anemia is expected to dominate the total iron-binding capacity reagents market due to higher prevalence of the disease. By end user, the global total iron-binding capacity reagents market is expected to be dominated by diagnostic laboratories owing to higher patient footfall for the diagnosis. Manufacturers in the global total iron-binding capacity reagents market are engaging in various collaboration activities to enhance their revenue generation via increased sale of total iron-binding capacity reagents.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10626

Total Iron-Binding Capacity Reagents Market: Regional Outlook

The global total iron-binding capacity reagents market is expected to be dominated by the North America due to higher prevalence of the iron deficiency related anemia in the region. Europe is expected to be the second most revenue generating region in global total iron-binding capacity reagents market owing to higher number of procedures carried out in the region. Latin America is expected to witness steady growth over the forecast period owing to increasing product availability. Asia-Pacific total iron-binding capacity reagents market is expected to witness significant growth owing to rapidly increasing number of procedures carried out in China and India. Middle East and Africa total iron-binding capacity reagents is expected to be the least lucrative region due to lower demand of the product.

Total Iron-Binding Capacity Reagents Market: Key Players

The key participants operating in the global total iron-binding capacity reagents market are: Biosystems S.A., Randox Laboratories Ltd., Sekisui Diagnostics, Thermo Fisher Scientific, Henry Schein, Inc., and others.

The report covers exhaust analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Indication
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-10626